- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04592146
Maintaining and imPrOving the intrinSIc capaciTy Involving Primary Care and caregiVErs (POSITIVE)
POSITIVE: Maintaining and imPrOving the intrinSIc capaciTy Involving Primary Care and caregiVErs
The POSITIVE platform offers the possibility of unsupervised monitoring of pre-frailty and frailty status in a community setting, to detect the onset of frailty and to assess its evolution.
The primary objective of the study is to evaluate whether the POSITIVE system improves frailty in at least 1 point in the Fried's Criteria and 5 points in the FTS-5.
This is a multi-centre, non-inferiority, randomized, simple blind and prospective pilot study with a 12-month follow up duration. The study will be carried out in Spain, Sweden and Poland. 150 participants will be randomized into two groups. The control group will receive usual medical care. The intervention group will receive, in addition, the POSITIVE frailty home monitoring and intervention system.
Study Overview
Status
Conditions
Detailed Description
The primary endpoints is to evaluate whether a multimodal intervention supported by the POSITIVE technological ecosystem improves frailty in at least 1 point in Fried's Criteria and 5 points in FTS-5 during a 6-month follow-up period.
This objective will be investigated through a multi-centre, non-inferiority, randomized, simple blind and prospective pilot study with an intervention lasting for 6 months. The study will be carried out in Spain, Sweden and Poland. 150 participants (50 per site) will be randomized into two groups. The control group will receive usual medical care. The intervention group will receive, in addition, the POSITIVE frailty home monitoring and intervention system.
Both groups will be assessed with the same instruments. This assessment will be conducted at baseline (in the beginning of the trial period), at the middle (month 3) and at the end of the intervention (month 6).
A stratified randomization technique will be applied in each of the study groups based on: age group (70-85,> 85), history of cognitive impairment, history of stroke to guarantee the existence of comparable groups. These factors have been significantly associated with frailty and pre-frailty status (stroke OR =3.11 (1.05-9.18), age, per 1-year OR = 1.14 (1.08-1.21); cognitive impairment OR = 8.37 (4.43-15.83)).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lodz, Poland, 90-419
- Not yet recruiting
- Medical University of Lodz
-
Contact:
- Tomasz Kostka, PhD
- Phone Number: 251 +48 426793144
- Email: tomasz.kostka@umed.lodz.pl
-
Principal Investigator:
- Tomasz Kostka, PhD
-
Sub-Investigator:
- Małgorzata Pigłowska, MsC
-
-
-
-
Madrid
-
Getafe, Madrid, Spain, 28905
- Recruiting
- Fundación para la Investigación Biomédica - Hospital Universitario de Getafe
-
Contact:
- Rodrigo Pérez-Rodríguez, PhD
- Phone Number: +34657994364
- Email: rprodrigo@salu.madrid.org
-
Principal Investigator:
- Leocadio Rodríguez-Mañas, PdD
-
Principal Investigator:
- Rodrigo Pérez-Rodríguez, PhD
-
-
-
-
-
Stockholm, Sweden, 14183
- Not yet recruiting
- Karolinska Institutet
-
Contact:
- Susanne GE Guidetti, PhD
- Phone Number: +46 (0)739 661636
- Email: susanne.guidetti@ki.se
-
Principal Investigator:
- Susanne GE Guidetti, MsC
-
Sub-Investigator:
- Minna Terio, PhD
-
Sub-Investigator:
- Marina Taloyan, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age ≥ 70.
- Living at home.
- Having a caregiver/relative and/or supervision at home.
- Barthel ≥ 90.
- Meet at least 1 criterion from Fried's Criteria.
Exclusion criteria:
- Inadequate home infrastructure to host the required technology.
- Inability to understand on how to use the POSITIVE system by the participant.
- Diseases that may affect prescription therapy:
- History of alcohol/drugs abuse.
- Living with another participant.
- Participating in other clinical studies.
- Three or more hospitalizations in the last year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Control group
Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care).
Frailty care will consist in a multicomponent intervention.
|
This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
|
EXPERIMENTAL: Intervention group
Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person. As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected. |
This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb.
Furthermore, through a tablet device, other relevant information (e.g.
state of mind, activities of daily living-ADLs, etc.) is collected.
The same device is used to enhance communication with the clinical team and follow the tailored intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frailty status 1
Time Frame: 6 months
|
Evaluation of the impact of the technology supported intervention in terms of frailty measured with the Linda Fried's criteria.
This test ranges from 0 to 5 (0: robust; 1-2: pre-frailty; +2: frailty).
|
6 months
|
Frailty status 2
Time Frame: 6 months
|
To evaluate whether a multimodal intervention supported by the POSITIVE technological ecosystem improves frailty in at least 5 points in Frail trait scale (FTS-5) during a 6-month follow-up period.
FTS scores between 0-50.
0 is the best value and 50 the worst value.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frailty trajectories 1
Time Frame: 6 months
|
Trajectories of frailty according to changes in Fried´s phenotype.
Fried´s Phenotype scores between 0 and 5. 0 means robust; 1-2 mean pre-frail and 3 or more mean frail
|
6 months
|
Frailty trajectories 2
Time Frame: 6 months
|
To evaluate whether the POSITIVE system improves frailty transitions in pre-frail and frail participants according to FTS-5.
|
6 months
|
Physical function 1
Time Frame: 6 months
|
To evaluate whether the POSITIVE system improves participants' physical performance according to the Short Physical Performance Battery (SPPB).SPPB scores between 0-12.
0 is the worst and 12 the best value.
|
6 months
|
Physical function 2
Time Frame: 6 months
|
To evaluate whether the POSITIVE system improves participants' physical performance according to the Gait Speed test (meters/second)
|
6 months
|
Basic activities daily living (BADL)
Time Frame: 6 months
|
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (basic activities) according to the Barthel Index.
Barthel scores between 0-100; 0 is the worst value and 100 the best.
|
6 months
|
Disability
Time Frame: 6 months
|
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (instrumental activities) according to WHO Disability Assessment Schedule (WHODAS 2.0).
Score between 0 to 100 (where 0 = no disability; 100 = full disability)
|
6 months
|
Instrumental activities of daily living (IADL)
Time Frame: 6 months
|
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (instrumental activities) according to the Lawton and Brody scale.
Lawton and Brody scale scores between 0-10; 0 is the worst and 10 the best value.
|
6 months
|
Health-related quality of life
Time Frame: 6 months
|
To evaluate the influence of the POSITIVE system in the quality of life according to the European Quality of life 5 dimensions-5 levels (EuroQoL 5D-5L).
EuroQoL scores between 0-10 and 10 is the worst quality of life.
|
6 months
|
Cognitive impairment 1
Time Frame: 6 months
|
To evaluate the influence of the POSITIVE system in the cognitive sphere according to the MONTREAL COGNITIVE ASSESSMENT (MoCA test).
Scores between 0-30 being 30 the best value.
|
6 months
|
Cognitive impairment 2
Time Frame: 6 months
|
To evaluate the influence of the POSITIVE system in the cognitive sphere according to the clock drawing test.
Score ranges between 0-10.
<8 suggests that cognitive impairment (CI)
|
6 months
|
Affective sphere
Time Frame: 6 months
|
To evaluate the influence of the POSITIVE system in the affective sphere according Geriatric Depression Scale (GDS). Each answer indicating depression (bold 'yes' or 'no) counts one point. Scores greater than 5 are indicative of probable depression. In the experimental site located in Sweden, the version of this scale will be used. |
6 months
|
Caregiver quality of life
Time Frame: 6 months
|
To evaluate the influence of the POSITIVE system on the caregiver quality of life according EuroQoL-5D-5L.
|
6 months
|
To evaluate the usability of the POSITIVE system according to the System Usability Scale (SUS).
Time Frame: 6 months
|
SUS ranges from 0 to 100.
A SUS score above a 68 would be considered above average and anything below 68 is below average..
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Leocadio Rodríguez-Mañas, MD, PhD, Hospital Universitario de Getafe
- Principal Investigator: Rodrigo Pérez-Rodríguez, PhD, FIB-Hospital Universitario de Getafe
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- POSITIVE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frail Elderly Syndrome
-
DSM Nutritional Products, Inc.CompletedFrail Elderly | Pre-frail ElderlyNetherlands
-
McMaster UniversityAlberta Health services; Saskatchewan Health Authority - Regina Area; Canadian... and other collaboratorsActive, not recruitingFrail Elderly SyndromeCanada
-
Università degli Studi del Piemonte Orientale "Amedeo...Completed
-
University of Massachusetts, WorcesterAnesthesia Patient Safety FoundationCompleted
-
School of Health Sciences GenevaInstitution genevoise de maintien à domicileCompletedFrail Elderly Syndrome
-
University of GlasgowNHS Greater Glasgow and ClydeUnknownFrail Elderly SyndromeUnited Kingdom
-
Pirogov Russian National Research Medical UniversityActive, not recruitingFrail Elderly SyndromeRussian Federation
-
The University of Hong KongSimon K.Y.Lee FoundationCompletedFrail Elderly SyndromeHong Kong
-
Hospital Israelita Albert EinsteinFundação de Amparo à Pesquisa do Estado de São PauloCompletedFrail Elderly SyndromeBrazil
Clinical Trials on Frailty multicomponent intervention
-
Duke-NUS Graduate Medical SchoolCompleted
-
Servicio Canario de SaludInstituto de Salud Carlos IIICompletedSystemic Lupus ErythematosusSpain
-
University Rovira i VirgiliDiputació de TarragonaCompletedDiet Modification | Food Preferences | Diet Habit | Food Allergy | Food Intolerance | InterventionSpain
-
University of PittsburghHealth Resources and Services Administration (HRSA)Completed
-
Chang Gung Memorial HospitalRecruiting
-
Universiti Putra MalaysiaCompleted
-
Duke-NUS Graduate Medical SchoolRecruitingChronic Kidney DiseasesSingapore
-
Lawson Health Research InstituteCanadian Institutes of Health Research (CIHR); Institute for Clinical Evaluative... and other collaboratorsCompletedKidney Diseases | End Stage Renal Disease | Kidney FailureCanada
-
Consorci Hospitalari de VicUnknownQuality of Life | Alzheimer Disease | CaregiversSpain
-
Chang Gung Memorial HospitalMinistry of Health and Welfare, TaiwanRecruiting